EZMEKLY 1mg dispersible tablets medication leaflet

L01EE05 • mirdametinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mitogen-activated protein kinase (MEK) inhibitors

Mirdametinib is a medicine used in people with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that cannot be completely removed by surgery without major risk. It may be used in adults and children according to the specialist’s recommendation.

The medicine blocks MEK, a protein involved in cell growth signalling. By doing this, it may reduce tumour size or symptoms such as pain, limited movement or impaired function. The benefit is assessed through clinical examinations, symptom review and imaging tests.

Mirdametinib is taken by mouth according to a strict schedule, sometimes with planned treatment breaks. Taking the doses correctly is important. Before and during treatment, eye examinations, heart assessment and blood tests, including muscle enzyme tests, may be required.

Common side effects include rash, diarrhoea, nausea, vomiting, muscle or joint pain, tiredness, abdominal pain, headache and inflammation around the nails. Contact your doctor urgently if you develop blurred vision, eye pain, palpitations, breathing difficulty, swelling, severe muscle weakness or a widespread rash.